Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of cancer. The company's pipeline includes a diverse portfolio of small molecule drug candidates that target cancer cells with specific genetic mutations.

Kura's lead product candidate, ziftomenib, is a potent and selective inhibitor of the menin-KMT2A/MLL interaction for the treatment of genetically defined acute myeloid leukemia (AML) patients. The company is also advancing other clinical-stage programs, including tipifarnib for the treatment of head and neck squamous cell carcinoma (HNSCC) and other solid tumors.

The company's business model is centered on the research, development, and commercialization of its proprietary drug candidates. Kura Oncology collaborates with academic institutions and other biopharmaceutical companies to advance its pipeline and bring new cancer therapies to patients in need. The company's primary market is the global oncology market, with a focus on addressing unmet medical needs in specific patient populations.

Keywords: biopharmaceutical, precision medicine, oncology, cancer treatment, clinical-stage, small molecule drugs, acute myeloid leukemia, solid tumors, drug development, targeted therapy